An analgesic pathway from parvocellular oxytocin neurons to the periaqueductal gray in rats

Supplementary Information

Mai Iwasaki^{1,#}, Arthur Lefevre^{1,2,+,#}, Ferdinand Althammer^{2,3,4,#}, Etienne Clauss Creusot^{1,#}, Olga Łąpieś¹, Hugues Petitjean¹, Louis Hilfiger¹, Damien Kerspern¹, Meggane Melchior¹, Stephanie Küppers², Quirin Krablicher², Ryan Patwell², Alan Kania², Tim Gruber⁵, Matthew K. Kirchner³, Moritz Wimmer⁴, Henning Fröhlich⁴, Laura Dötsch⁴, Jonas Schimmer², Sabine C, Herpertz⁶, Beate Ditzen^{7,8}, Christian P. Schaaf^{4,8}, Kai Schönig⁹, Dusan Bartsch⁹, Anna Gugula¹⁰, Aleksandra Trenk¹⁰, Anna Blasiak¹⁰, Javier E. Stern³, Pascal Darbon¹, Valery Grinevich^{2,3,§,*}, Alexandre Charlet^{1,§,*}

¹ Centre National de la Recherche Scientifique and University of Strasbourg, Institute of Cellular and Integrative Neuroscience, 67000 Strasbourg, France

² Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim 68159, Germany

³ Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA

⁴ Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany

⁵ Van Andel Institute, Grand Rapids, MI, USA

⁶ Department of General Psychiatry, Center of Psychosocial Medicine, University of Heidelberg, 69115, Heidelberg, Germany

⁷ Institute of Medical Psychology, Heidelberg University Hospital, 69115, Heidelberg, Germany

⁸ Ruprecht-Karls University Heidelberg, Heidelberg, Germany

⁹ Department of Molecular Biology, Central Institute of Mental Health, University of Heidelberg, Mannheim 68159, Germany

¹⁰ Department of Neurophysiology and Chronobiology, Institute of Zoology and Biomedical Research, Faculty of Biology, Jagiellonian University, Krakow, 30-387, Poland

+ Present address: Cortical Systems and Behavior Laboratory, University of California, San Diego, La Jolla, CA 92093, USA

These authors contributed equally

§ These authors jointly supervised this work

a, Schema of the generation of knock-in OTR-Cre rats.

b, As a further control, DNAs of Cre positive animals were used for detection of homologous recombination at the OT locus. For this purpose, the targeted region was amplified by PCR using the Q5 polymerase (NEB) with 100-200ng of genomic DNA as template. Primers were selected which bind up- and downstream of the insertion site (outside of the homology arms) and were each combined with a primer located within the IRES2-Cre construct. We used for the 5' insertion site the primers OT upper_check (5' CTCCCAGGGAAGATCTGTACC 3') together with IRES2_rev (5' GCTTCGGCCAGTAACGTTAGG 3') and for the 3' site the primers CRISPR_bGH_for (5' gacaatagcaggcatgctgg3') together with OT_rev_hom (5' GGGTTTTCCCAGAACTCAGC 3').

c, Injection schema for the labelling of OTR neurons in the OTR-Cre rats. The rAAV_{1/2}-EF1 α -DIO-GFP is injected into the PAG.

d-f, Images showing GFP (green) and DAPI (blue) staining, at various distances from Bregma, in the vIPAG of OTR-Cre rats injected with the EF1 α -DIO-GFP rAAV. Scale bar = 100 μ m. Aq = Aqueduct.

h-i, TGOT-induced increase of AP frequency of GFP-negative neurons in the PAG of female rats. **h**, Example traces from a GFP-negative cell under baseline, TGOT application, and wash out conditions. **i**, Quantification of TGOT effect on AP frequency of GFP-negative neurons (Baseline 0.119 \pm 0.046 Hz vs TGOT 0.108 \pm 0.049 Hz vs Wash 0.122 \pm 0.064 Hz; Friedman's test = 1.6, p = 0.48, n_{cells} = 9).

j-m, TGOT-induced change in first spike latency (FSL) of GFP-negative neurons in the PAG of female rats. **j**. Representative evoked currents in a GFP-negative neuron in response to a square current step (50 pA; 800 ms) in baseline (black line) and oxytocin (blue line) conditions. **k**, FSL quantification for GFP-negative neurons (OTR⁻) during a square current step: no differences were found between the baseline condition (31.95 \pm 9.44 ms) and after the TGOT incubation 37.08 \pm 14.89 ms, non significative (n.s.) p = 0.788 (paired two-tailed t test, n_{cells} = 7). **I**, Proportion of neuron after TGOT incubation with a decrease of the FSL (n = 1/7, blue); an increase (n = 2/7, red) or without a variation of \pm 10 ms (no effect, gray (n = 4/7). **m**, Quantification of TGOT effect on AP frequency of GFP-negative neurons during a square current step (Baseline 7 \pm 2.012 spikes vs TGOT 7.857 \pm 2.604 spikes; Wilcoxon signed-rank test = 6, p = 0.6845 (two-sided), n_{cells} = 7.

Data are represented as mean ± sem and as individual paired points. Source data are provided as a Source Data file.



a, RNAscope for OTR and Cre mRNA probes. Enlarged insets highlight co-localization of OTR and Cre probe signals. Aq=aqueduct, DR=dorsal raphe nucleus, vIPAG=ventrolateral periaqueductal gray.

b, Quantification of OTR/Cre and Cre/OTR probe signals from n = 3 rats (3 sections each). Results are expressed as the mean \pm SEM and the individual points of each conditions are represented as white circle.

c, Confocal images show the vIPAG of a OTR-IRES-Cre rat injected with a cre-dependent rAAV expressing GFP that was counterstained with a cre antibody. High magnification images highlight co-localization of cre protein and GFP signals.

d, Quantification of cre+ GFP-expressing cells in vIPAG (GFP/Cre). Results are expressed as the mean ± SEM and the individual points of each conditions are represented as white circle.

e, Uncut western blot of WT and OTR-IRES-Cre (KI) rats using a cre antibody.

f, Enlarged inset shows presence of specific cre band (35kDa) in a KI, but not WT rat.

Source data are provided as a Source Data file.

а

b

e



С





d



OTR-IRES-Cre rat

Uncut western blot



f

WT Ladder OTR-Cre



Cre-recombinase Gapdh

Schematic depiction of experimental procedures. WT and OTR-IRES-Cre rats were subjected to stereotaxic injection of various viral vectors at 10-12 weeks of age. Rats were then allocated to either neuroanatomical or physiological studies and processed accordingly. Images were created using BioRender.



a, Unilateral stereotaxic injection of WT rats (n=3 male and n=3 female) into the SON and PVN using rAAV_{1/2}-EF1 α -mCherry or rAAV_{1/2}-EF1 α -GFP, respectively.

b, Verification of injection sites and correct expressing of viral fluorescent proteins in the respective nuclei.

c, Analysis of OTergic fiber laterality within the vIPAG of male and female rats and various Brema levels. Note that OT fibers are prominently labeled in both hemispheres (i.e. left and right vIPAG) following unilateral injections into the PVN.



Merge

a-b, Distinction of parvocellular (parvOT) and magnocellular (magnOT) OT-neuron populations. **a,** Schema for the identification of magnOT and parvOT neurons: injection of green retrobeads into the PAG, staining for OT (red) and central application of fluorogold (FG, blue), which labels only magnOT neurons. **b,** Image of retrolabeled neurons containing fluorescent beads (green) as well as staining for Fluorogold (blue) and OT (red). White arrows indicate the co-localization of OT and FG (magnOT neuron) and the white asterisk indicates the co-localization of retrobeads and OT. Scale bars = $25 \,\mu\text{m.} \,\text{n} = 3$ female rats.

c-f, Retrograde labelling of projections from PVN OT-neurons to the vIPAG and SC. **c**, Schema of the experimental design with injection site of green retrobeads in the vIPAG (**d**) and red retrobeads in the SC (L5, **e**). Scale bars = 200 μ m. **f**, Image of PVN OT-neurons (blue) projecting either to the vIPAG (green, white asterisk) or to the SC (red, white arrow). No OT neuron containing both red and green retrobeads was found. Aq = Aqueduct. 3v = third ventricle. Scale bar = 50 μ m. n = 4 female rats.

g-h, PAG-projecting PVN OT-neurons from Figure 2B do not target the SC or SON. **g**, Schema of viral injection showing injection of rAAV_{1/2}-OTp-DIO-GFP in the PVN and rAAV-CAV2-Cre in the vIPAG of WT rats. **h**, Images of slices from the spinal cord at different levels (cervical, C3; thoracic, T7; lumbar, L4) and from the SON. No GFP fibers were found. Scale bars = 200 μ m. n = 2 female rats.

i-j, SON-projecting PVN OT-neurons target the SC but not the vIPAG. **i**, Schema of viral injection showing injection of rAAV_{1/2}-OTp-DIO-GFP in the PVN and rAAV-CAV2-Cre in the SON of WT rats. **j**, **Left** Images of PVN OT-neurons (red) expressing GFP (green) projecting fibers to the SC (L5, NeuN in red, scale bars = 100 μ m). **Right** Image of the vIPAG showing no GFP positive fibers. Scale bar = 100 μ m. n = 4 female rats.

k-I, SC-projecting PVN OT-neurons target the SON but not the vIPAG. **k**, Schema of viral injection showing injection of rAAV_{1/2}-OTp-DIO-GFP in the PVN and rAAV-CAV2-Cre in the SC of WT rats. **I** Left Images of PVN (scale bars = 40 μ m) OT-neurons (red) expressing GFP (green) projecting fibers to the SON (scale bar = 100 μ m). opt = optic tract. **Right** Image of the vIPAG showing no GFP positive fibers. Aq = aqueduct. Scale bar = 100 μ m. n = 4 female rats.



Scheme depicting the respective projections of the two different neuronal populations of parvOT and their projections to spinal cord (Eliava et al., 2016) and to vIPAG (present manuscript). Given that the oxytocinergic innervation of the PAG appears to be higher by roughly 2-3-fold, we speculate that approximately 50-70 parvocellular OT cells might project to the vIPAG compared to the approximately 30 parvocellular OT cells that we previously reported for the spinal cord.

Distribution map of distinct parvocellular oxytocinergic projections from PVN to PAG and SC





PVN 2400 OT cells total 70-200 parvOT cells



Bregma -11.0mm



PAG Projections of 50-70? parvOT cells **SC** Projections of 30 parvOT cells

a, Pipeline for Imaris-assisted 3D reconstruction based on raw IHC images.

b-c, Confocal images showing OT fibers and OTR-positive neurons in the vIPAG. **b**, Images of OTR neurons (green), OT fibers (magenta), vGluT2 (red) and DAPI (blue). Scale bar = 100 μ m. **c**, Overlay. Scale bar = 100 μ m.

d, Automated quantification of the number of SYN positive voxels in GFP-positive and negative neurons reveals no difference in overall synaptic input. n = 4 rats, 8 images per animal, p=0.6689, two-tailed student t-test. Results are expressed as the mean ± SEM and the individual points of each conditions are represented as white circle.

e, Analysis of somatic volume reveals no difference between OTR-positive (n = 496) and OTRnegative (n = 3840) soma sizes. n = 4 rats, 8 images per animal, p = 0.8104, two-tailed student ttest. Results are expressed as the mean \pm SEM and the individual points of each conditions are represented as white circle.

f, Quantification of Syn+ OTergic fibers in vIPAG at various Bregma levels.

Individual data and statistics are presented in Source Data File. Results are expressed as the mean \pm SEM and the individual points of each conditions are represented as white circle.

Source data are provided as a Source Data file.





a, Visualization of the last step of spike sorting- superparamagnetic clustering (ascription of spikes to their corresponding neurons). This step is preceded by 1) automatic spike detection based on amplitude threshold and feature extraction – wavelets coefficients. From left to right: superimposed clusters, cluster separation and unassigned spikes based on spike shapes

b, Spike shapes represented in each channel of the tetrode.

c, Cluster 3 (from B) detailed profile, depicting (from left to right, and up to down) spikes' waveforms, baseline & peak voltages, spikes waveform variability over time, spikes parameters, stability presented as spikes count/time, activity during interspikes intervals of different length, density plots, waveform of selected spikes, PSTH, waveforms detected around an event and spikes distribution.

d, Onset, peak and offset of BL-induced excitation in the vIPAG. Onset is defined as the first time point when the spike rate exceeded the threshold ($BS_{mean} + 4BS_{SD}$); BS_{mean} represents the mean firing rate of the baseline period, and BS_{SE} is the standard deviation of firing rate during the baseline period. Offset is defined as the last time point when the spike rate fell below the threshold for more than 20 s during the 300 s following BL ($n_{cells} = 21$).

e, Number of active cells in each single second. "Active" defined by a spike rate above the threshold $(BS_{mean} + 4BS_{SD})$ (n = 21).

f, Image showing a representative recording site in the vIPAG. Dotted line indicates placement of the optic fiber. Aq = aqueduct. Scale bar = $100 \mu m$.

Source data are provided as a Source Data file.



Aq

a, Scheme of electrophysiological recordings from SC in female rats.

b, Box plot showing maximum activity, minimum activity, and half activity latencies. Whiskers indicate the minimum and maximum latency. Colored box shows the range between 1st and 3rd quantile, median is depicted as vertical line. Unpaired Wilcoxon rank sum tests were performed. WT n=8, ChR2 n=15 (1st quartile, median, 3rd quantile); Latency to reach the maximum WU (s) [WT:(26.00, 31.50, 46.00), ChR2: (26.25, 35.00, 55.75)] not significant (p = 0.85); latency to reach the half reduction of WU (s) [WT: (75.50, 96.50, 163.00), ChR2 (64.25, 83.00, 125.75)] not significant (p = 0.32); or latency to reach the maximum reduction of WU (s) [WT (183.00, 209.00, 263.00), ChR2 (198.50, 250, 269.75)] not significant (p=0.50).

c-h, vIPAG BL effect on the spike rate of WDR's A δ -fiber discharge. **c**, Mean time course observed after vIPAG BL in control rats (gray, n_{cells} = 8) and OT ChR2-expressing rats (blue, n_{cells} = 14). Left and right panels show two consecutive recordings separated by 300 s. Line shadows represent SEM. **d**, Percentage of reduction expressed as the minimum level activity observed after a wind-up plateau phase, 140 – 180 s; Unpaired Wilcoxon rank sum test (two-sided); Ctrl (n_{cells} = 8) 34.08 ± 4.73 vs ChR2 (n_{cells} = 14) 51.26 ± 4.1%, U = 27, p = 0.0337 and **e** 570 – 600 s after BL onset. Unpaired Wilcoxon rank sum test (two-sided); Ctrl (n_{cells} = 14) 33.88 ± 5.12 %, U = 37, p = 0.2119. **f**, Mean time course observed after vIPAG BL in OT ChR2-expressing rats (blue, n_{cells} = 6), and in the same recordings after dOVT injection in the vIPAG (red, n_{cells} = 6). Left and right panels show two consecutive recordings separated by 300 s. Line shadows represent SEM. **g**, Percentage of reduction expressed as the minimum level activity observed after a wind-up plateau phase, 140 – 180 s; Paired Wilcoxon signed rank test (two-sided); ChR2 50.38 ± 8 vs dOVT 30.36 ± 5.46 %, W = -19, p = 0.0625, n_{cells} = 6 and **h** 570 – 600 s after BL onset. Paired Wilcoxon signed rank test (two-sided); ChR2 50.36 ± 8 vs dOVT 30.36 ± 5.46 %, W = -19, p = 0.0625, n_{cells} = 6 and **h** 570 – 600 s after BL onset. Paired Wilcoxon signed rank test (two-sided); ChR2 50.38 ± 8 vs dOVT 30.36 ± 5.46 %, W = -19, p = 0.0625, n_{cells} = 6 and **h** 570 – 600 s after BL onset. Paired Wilcoxon signed rank test (two-sided); ChR2 50.78 ± 8 vs dOVT 30.36 ± 5.46 %, W = -19, p = 0.0625, n_{cells} = 6 and **h** 570 – 600 s after BL onset. Paired Wilcoxon signed rank test (two-sided); ChR2 50.58, n_{cells} = 6.

i-n, vIPAG BL effect on the spike rate of WDR's Aβ-fiber discharge. **i**, Mean time course observed after vIPAG BL in control rats (gray, n = 8) and OT ChR2-expressing rats (blue, n = 14). Left and right panels show two consecutive recordings separated by 300 s. Line shadows represent SEM. **j** Percentage of reduction expressed as the minimum level activity observed after a wind-up plateau phase, 140 – 180 s; Unpaired Wilcoxon rank sum test (two-sided); Ctrl (n=8) 24.44 ± 10.14 vs ChR2 (n=15) 27.39 ± 7.91%, U = 55, p = 0.7763, and **k** 570 – 600 s after BL onset. Unpaired Wilcoxon rank sum test (two-sided); CTRL (n=8) 44.7 ± 13.23 vs ChR2 (n=14) 33.43 ± 10 %, U = 53, p = 0.8676. **I** Mean time course observed after vIPAG BL in OT ChR2-expressing rats (blue, n_{cells} = 6), and in the same recordings after dOVT injection in the vIPAG (red, n_{cells} = 6). Left and right panels show two consecutive recordings separated by 300 s. Line shadows represent SEM. **m** Percentage of reduction expressed as the minimum level activity observed after a wind-up plateau phase, 140 – 180 s; Paired Wilcoxon signed rank test (two-sided); ChR2 21.28 ± 10.25 vs dOVT 37.89 ± 8.12 %, W = 11, p = 0.3125, n = 6 and **n** 570 – 600 s after BL onset. Paired Wilcoxon signed rank test (two-sided); ChR2 20.14 ± 3.39 vs dOVT 34.58 ± 5.13 %, W = 17, p = 0.0938, n_{cells} = 6.

Results are expressed as the mean ± SEM and the individual points of each conditions are represented as white circle. Source data are provided as a Source Data file.



a-c, Optogenetic stimulation of the vIPAG in the chronic constriction of the sciatic nerve (CCI) model of neuropathic pain in female rats. **a**, Schema of the injection of rAAV_{1/2}-OTp-ChR2-mCherry in the PVN and optic fiber implantation in the PAG. **b-c** Graphs showing the threshold response to mechanical stimuli in female rats optogenetically stimulated in vIPAG (as in Figure 6C and 6D). The effect of vIPAG-BL was measured at 5 min, 1 h and 3 h after vIPAG-BL on the CFA contralateral side (**b**) as well as CCI contralateral side (**c**). All results are expressed as average ± SEM. (**b**) 2-way RM ANOVA, F_{treatment} = 8.391; p = 0.178, n_{rats} = 10. (**c**) 2-way RM ANOVA, F_{treatment} = 9.319; p = 0.2331, n_{rats} = 10.

d-e, Verification for the expression of Gq-mCherry in the vIPAG. **d**, Schema of the injection of rAAV_{1/2}-EF1 α -DIO-Gq-mCherry in the PAG. **e**, Image showing the expression of rAAV_{1/2}-EF1 α -DIO-Gq-mCherry (red) with staining for DAPI (blue). Scale bar = 100 μ m. Aq = aqueduct.

f-g, Thermal pain threshold of male rats expressing Gq-mCherry (red) or mCherry only (gray) in vIPAG OTR neurons after DCZ administration during normal or inflammation (CFA) conditions.

f, Mechanical pain threshold after DCZ administration in the CFA paw of male rats expressing GqmCherry (blue) or mCherry only (gray) in vIPAG OTR neurons. 2-way RM ANOVA test (F_{interaction} = 17.79; p < 0.0001; n_{rats} = 6), followed by multiple comparison post-hoc test with Dunnett correction: Gq-mCherry, 0 vs 20: **p_{adj} = 0.0033. **g**, Thermal pain threshold after DCZ administration in the CFA paw of male rats expressing Gq-mCherry (red) or mCherry only (gray) in vIPAG OTR neurons. 2way RM ANOVA test (F_{interaction} = 40.40; p < 0.0001; n_{rats} = 6), followed by multiple comparison post-hoc test with Dunnett correction: Gq-mCherry, 0 vs 20: ***p_{adj} = 0.003; 0 vs 60: **p_{adj}: = 0.0077; mCherry, 0 vs 180: **p = 0.0058. Blue asterisks correspond to the statistic done on the Gq-mCherry group while black asterisks to the mCherry group.

h, Schema depicting the experimental timeline of the CPP protocol.

All results are expressed as average ± SEM. Source data are provided as a Source Data file.

